Connect your AI

BridgeBio Pharma BBIO Equity in earnings (losses) of equity method investees

Equity in earnings (losses) of equity method investees at other companies

Arrowhead ResearchARWR

——

Segments

By segment

Reportable Segment-$18.28M—

Other financials

Income statement

Revenue$194.5M+66.8%

Gross profit$184.6M+61.9%

Operating income-$106.0M-1.5%

Net income-$166.6M+1.8%

EPS (diluted)-$0.84+4.5%

Balance sheet

Cash & equivalents$882.0M+62.5%

Total debt$3.3B+32,101%

Total equity-$2.3B-38.2%

Total assets$1.4B+55.5%

Cash flow

Operating cash flow-$197.3M+1.0%

CapEx$69.0K—

Free cash flow-$197.3M+0.9%

Valuation

Market cap$12.98B+119%

Enterprise value$15.36B+178%

P/S22.4×-24.1×

Profitability

Gross margin95.1%-0.2pp

Operating margin-90.5%-41.2pp

Net margin-125.9%-54.5pp

FCF margin-76.8%—

Returns & leverage

Return on equity-216.8%—

Debt / equity2×—

Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's equity in earnings (losses) of equity method investees.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is BridgeBio Pharma's equity in earnings (losses) of equity method investees?: BridgeBio Pharma (BBIO) reported equity in earnings (losses) of equity method investees of -$18.28M in Q1 2026.
How has BridgeBio Pharma's equity in earnings (losses) of equity method investees changed year-over-year?: BridgeBio Pharma's equity in earnings (losses) of equity method investees decreased by 17.5% year-over-year, from -$15.56M to -$18.28M.